Description: Patrys Limited is engaged in the commercialization of its technologies to develop natural human antibody-based therapeutic products for the treatment of cancer. The Company is engaged in conducting research and development activities in the biopharmaceutical sector. The Company's products include PAT-SM6, PAT-LM1 and PAT-SC1. PAT-SM6 is a natural human antibody that binds to multiple types of cancer, including solid tumors, such as melanoma, breast, colon and pancreatic, as well as blood-based cancers, such as multiple myeloma. PAT-SM6 has completed its Phase I clinical trials for melanoma and Phase I/IIa clinical trials for multiple myeloma. PAT-LM1 is a natural human antibody that can be used for treatment of multiple types of cancer, with potency against colon, lung, breast, ovary and pancreatic cancers. PAT-LM1 is in pre-clinical stage of its study. It offers 3E10 Deoxymab, a lupus autoantibody. It is toxic to cancer cell that has deficiencies in deoxyribonucleic acid repair.
Home Page: www.patrys.com
PAB Technical Analysis
Putnam Asset Allocation Funds
,
Phone:
61 3 9670 3273
Officers
| Name | Title |
|---|---|
| Dr. James A. Campbell B.Sc., MBA, Ph.D. | MD, CEO & Exec. Director |
| Ms. Valentina Dubljevic BSc, GAICD, MBB | VP of Scientific & Clinical Devel. |
| Dr. Deanne Greenwood B.Sc., GAICD, MBA, Ph.D. | VP of Bus. Devel. & Intellectual Property |
| Dr. Rebecca Tunstall | VP of Corp. Devel. |
| Mr. Stefan Ross | Company Sec. |
Exchange: AU
Country: AU
Currency: Australian Dollar (A$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.4427 |
| Price-to-Sales TTM: | 18.5117 |
| IPO Date: | 2007-07-20 |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |